NEW YORK, July 18 - Lynx Therapeutics reported second-quarter revenues of $4.4 million Wednesday, up 57 percent from the same period last year, and separately said BASF-LYNX, a joint venture with German chemical giant BASF, had agreed to license its Megaclone micro-bead DNA detection technology.

Lynx attributed the increase in revenue primarily to technology access fees that Lynx's customers paid for Megaclone technology. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.